#USA #Class Action #San Francisco #Hagens Berman #Gildan Activewear

Alert for Gildan Activewear Investors: Important Deadline Approaching

Hagens Berman, a distinguished national trial law firm with expertise in securities fraud and shareholder rights, is urging Gildan Activewear Inc. investors to take action regarding a class action lawsuit currently filed against the company in federal court. This alert particularly targets investors who have encountered substantial financial losses as a result of their Gildan stock investments. The crucial deadline for appointing a lead plaintiff is December 14, 2026.

Background of the Case

The lawsuit covers a specific class period from February 19, 2025, to June 15, 2026. According to the complaints referenced by Hagens Berman, Gildan and its executives allegedly made a series of false or misleading statements relating to the company's financial health and the drivers behind its sales growth.

Allegations Against Gildan

Key allegations from the class action claim that Gildan engaged in channel stuffing—a strategy where companies boost sales numbers by flooding the market with excess inventory. This practice can create an illusion of increased sales and revenue growth, which can mislead investors and inflate stock prices artificially. Some notable points of accusation include:

• - Gildan purportedly concealed its practice of channel stuffing, misrepresenting actual sales figures in order to enhance its reported performance metrics.
• - The company's growth was more a reflection of inflated sales through undisclosed inventory pushes rather than authentic market share expansion.
• - Specifics regarding Gildan’s acquisitions and strategic partnerships were allegedly overstated, particularly in relation to their dealings with HanesBrands, obscuring true operational metrics from investors.

Impact of the Investigative Report

The credibility of these claims gained momentum when, on June 16, 2026, a well-known activist short-seller, Jehoshaphat Research, published a critical report titled “Stuffing All of the Channel Some of the Time?” This comprehensive analysis revealed Gildan's reliance on premature sales recognition and overstocking distributors. Following this report, Gildan's stock experienced a sharp decline of $11.62 per share, amounting to a staggering 18.75% drop, leaving investors concerned about their investments.

What Affected Investors Should Do

For individuals who sustained significant losses during the specified class period, there is an opportunity to participate in the legal proceedings. Interested investors can submit their losses and consider seeking the position of lead plaintiff before the upcoming December 14, 2026 deadline. This designation allows individuals to take a leading role in the case, advocating for the interests of all class members.

Contact Information
Investors can reach out directly to Reed Kathrein, a partner leading the firm's securities practice group, via phone at (844) 916-0895 or through email at [email protected]. The firm emphasizes the importance of their ongoing investigation into the sales practices of Gildan, focusing on whether these impacted the company's reported revenue figures.

Additionally, there are options available for whistleblowers who may possess non-public information regarding Gildan's practices. Under the SEC's Whistleblower Program, individuals providing original information may receive rewards, potentially amounting to 30% of any resulting financial recovery.

About Hagens Berman

Hagens Berman is recognized for its commitment to holding corporate entities accountable and securing justice for investors, whistleblowers, and consumers impacted by corporate misconduct. The firm has successfully collected over $2.9 billion in settlements and continues to advocate for the rights of stakeholders affected by negligence. For ongoing updates, follow Hagens Berman on social media or visit their website at hbsslaw.com.

Investors should remain vigilant and proactive as legal landscapes evolve and protect their rights accordingly.